<DOC>
	<DOCNO>NCT01445002</DOCNO>
	<brief_summary>The study evaluate dose response immunotherapy grass pollen allergy use recombinant grass pollen vaccine BM32 . Efficacy analyze : - skin prick test - grass pollen inhalation challenge - antibody response . In addition , safety subcutaneous application BM32 evaluate .</brief_summary>
	<brief_title>Safety Dose Finding Trial BM32 Subjects Suffering From Grass Pollen Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>History seasonal allergic rhinitis grass pollen Normal electrocardiogram Moderate severe response approx . 1500 grass pollen grains/m3 2 hr exposure challenge chamber Positive skin prick test grass pollen within 12 month precede screen visit Positive RAST ( class 2 high ) timothy grass pollen rPhl p 1 + rPhl p 5 within 12 month precede screen visit Pregnant lactating female Females childbearing potential use medically acceptable birth control Structural nasal abnormality , nasal polyposis , history frequent nosebleed , recent nasal surgery ongoing upper respiratory tract infection Any respiratory disease mild asthma control occasional short act beta agonist normal lung function Current recent participation another clinical trial SIT grass pollen allergy last two year prior study Past present disease , may affect outcome trial , judge investigator Autoimmune diseases , immune defect include immunosuppression , immune complex immunopathies Suspected hypersensitivity ingredient study medication Use prohibit medication prior screen throughout study depot corticosteroid ( 12 week ) oral corticosteroid ( 8 week ) inhale corticosteroid ( 4 week ) Allergic symptoms time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>grass pollen allergy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>recombinant vaccine</keyword>
</DOC>